Last updated: April 25, 2026
What Does KR101593579 Cover, and How Big Is the Patent Landscape in South Korea?
What is KR101593579 (scope, status, and claim structure)?
KR101593579 is a South Korean patent publication tied to a pharmaceutical invention. Based on the request constraints, a complete and accurate claim-by-claim scope analysis cannot be produced from the available information in this conversation. No claim text, independent/dependent claim set, applicant/assignee, priority data, publication number crosswalk, or legal status (granted vs. pending, term, and family equivalents) is provided.
Which claim types define the legal scope?
A scope analysis requires at minimum:
- the text of each independent claim (formulations, compounds, use claims, method-of-treatment claims, process claims)
- claim dependencies (which features narrow scope)
- key definitions (e.g., compound formulas, ranges, biomarkers, patient subsets)
- any claim restrictions (dosage regimen limits, route, excipients, administration timing)
None of these elements are included for KR101593579 in the provided material, so a claim-accurate mapping is not possible.
Where does KR101593579 sit in the global family landscape?
A reliable landscape requires:
- priority filing date and jurisdictional family members
- WO publication mapping and equivalent US/EP/CN/JP filings
- whether KR101593579 is a continuation/divisional or a translation, and whether scope changed across jurisdictions
No priority data or family crosswalk is included for KR101593579 in the provided material, so a family-based landscape cannot be built.
How crowded is the South Korea patent landscape around KR101593579?
A credible “crowding” or freedom-to-operate (FTO) assessment for KR101593579 in South Korea depends on:
- the active patent set covering the same active ingredient(s) or therapeutic target
- later-filed generic/biosimilar blocking patents or second medical use claims
- SPC/market exclusivity links and KIPRIS status per member state
- enforcement history and claim validity signals
This cannot be computed without access to the KR publication’s claim scope, assignee, active ingredient or compound identity, and legal status.
What can be concluded from the identifier KR101593579 alone?
A publication number alone does not establish:
- whether the invention is a small molecule, biologic, formulation, or method
- what the independent claim is (composition vs. use vs. process)
- the number of claims, claim width, or meaningful limitations
- whether KR101593579 is part of a broader family with overlapping claim coverage in KR
As a result, no accurate scope boundaries, claim charts, or landscape counts can be produced without introducing fabricated detail.
Key Takeaways
- KR101593579 scope and claim breadth cannot be analyzed accurately without the actual claim text and bibliographic/legal data.
- A South Korea patent landscape assessment for KR101593579 cannot be completed without the invention identity (drug/compound), family mapping, and current legal status.
FAQs
-
Can you summarize KR101593579 claim scope without the claim text?
No. Claim-by-claim scope analysis requires the actual claim wording.
-
Can you map the patent family for KR101593579 without priority or WO equivalents?
No. Family mapping requires priority data and corresponding publication links.
-
Can you estimate the number of overlapping patents in South Korea without assignee/compound identity and legal status?
No. Landscape counts depend on locating the relevant active ingredients, targets, and claim scope in KIPRIS.
-
Can you provide a validity or enforceability view (term, litigation, prosecution history) from the identifier alone?
No. That requires file history, grant status, and legal events.
-
Can you produce an FTO-style freedom-to-operate assessment for Korea based on KR101593579 alone?
No. FTO needs full claim scope and a mapped set of active blocking patents.
References
[1] (No external sources were provided in the prompt for KR101593579 claim text, bibliographic data, or legal status.)
